Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SiroSkin: Topical Sirolimus for Skin Cancer Prevention
NCT05860881Phase 3Active, not recruiting
- Start
- Feb 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) comparing Topical Sirolimus with Placebo (2 arms). Primary endpoint: Keratinocyte Carcinoma development at 2 years. Started Feb 2024; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
squamous cell carcinoma (SCC)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT05860881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860881.